A, a woman in her 60s with hydrocephalus, recently had to postpone her scheduled surgery by about three weeks. Medical staff were available to perform the surgery, but the treatment material needed for it was in short supply.

Hydrocephalus is a condition in which cerebrospinal fluid builds up inside the head because it cannot drain properly. It can make walking difficult or impair cognitive function, and in severe cases, it can even worsen consciousness. Treatment uses a shunt, a thin tube and valve that drain cerebrospinal fluid toward the abdomen. It is like creating a new drainage route in place of the blocked pathway.

Korea University Ansan Hospital had initially secured a shunt for A's surgery, but two more urgent patients who had not been scheduled developed a need for the device, so it had to be used for them first. A ultimately had to wait until a new shunt arrived, and fortunately underwent surgery without a significant deterioration in her condition.

The problem is that such incidents are not limited to one hospital. Some hospitals have asked other hospitals to lend them shunts, while there have been cases in which surgeries were delayed while waiting for the materials. Newborns and infants in particular have less room than adults to postpone surgery, meaning that continued supply instability could lead to greater problems.

◇Before scheduling surgery, hospitals first check how many shunts remain
Shunt surgery is divided into ventriculoperitoneal, or VP, shunts, which connect the brain to the abdomen, and lumboperitoneal, or LP, shunts, which connect the lower back to the abdomen. LP shunts have recently been particularly unstable in supply. Kim Sang-dae, a professor of neurosurgery at Korea University Ansan Hospital, said, "In the past, there was almost no need to check inventory, but now we are in a situation where we have to keep track of how many shunts remain before surgery and how many patients are scheduled for surgery in the future."

Park Ki-soo, a professor of neurosurgery at Chilgok Kyungpook National University Hospital, recently received requests from three hospitals to lend LP shunt valves and tubes. The hospital lent two sets to one hospital two months ago, but it is now unable to accommodate additional requests because its own inventory is also running low. Park said, "Our hospital performs more than 200 LP shunt surgeries a year, so we receive products relatively as a priority," adding, "Even so, catheter supplies have recently been delayed, making it difficult to guarantee the schedule for future surgeries." He said he was also aware of cases in which surgeries at other hospitals had been delayed for more than two months. 

When LP shunts are unavailable, the surgical method can in some cases be changed to a VP shunt. VP shunts are also a standard treatment, but some elderly patients feel burdened by surgery that involves inserting a tube into the head. This means that the surgical method originally considered may have to be changed depending on the availability of materials.

◇Adults can wait several weeks, but infants have difficulty postponing surgery
Adults can have surgery rescheduled for several weeks later if their condition is stable, but newborns and infants may not be able to wait. Kim Sang-dae, who recently treated an infant with hydrocephalus who was about one month old, said, "When it is determined that a baby needs shunt surgery, it may have to be performed within a few days, or within a week at the latest," adding, "It is difficult to tell the family to wait another one or two weeks simply because a shunt is unavailable."   

As hydrocephalus worsens, cerebrospinal fluid presses on the brain, reducing consciousness and, in severe cases, leading to a coma. Shunts are needed not only for infants with congenital hydrocephalus but also for patients who develop hydrocephalus after a cerebral hemorrhage. Jang Won-seok, a professor of neurosurgery at Severance Hospital, said, "When hydrocephalus develops acutely, it is a matter connected to the patient's life," adding, "There are also situations in which patients have to get by with a temporary method of draining cerebrospinal fluid by connecting a tube outside the body because the necessary materials cannot be obtained."

◇Hospitals face shortages even without supply-disruption reports, exposing a vulnerable supply chain
According to the Ministry of Food and Drug Safety, all six approved shunt products that drain cerebrospinal fluid toward the abdomen are imported products. No official supply-disruption report has been filed for the LP shunt product from Medtronic that has been reported to be in short supply. However, Park Jun-beom, a professor of neurosurgery at Ulsan University Hospital and president of the Korean Hydrocephalus Research Society, said, "As the number of LP shunt surgeries has recently increased, a temporary supply shortage has occurred, and some hospitals have faced restrictions on use."

Meanwhile, a supply disruption has been reported for proGAV 2.0, a VP shunt valve from B. Braun Korea. MFDS said the disruption was temporary and resulted from a change in the manufacturer's location, adding that supply is expected to resume. The Ministry of Health and Welfare believes the necessary quantities can be supplied through other companies. 

The medical community is concerned about the supply structure itself. With only three major domestic suppliers and reliance on imports, supply disruptions could leave hospitals short of inventory. The Korean Hydrocephalus Research Society has called for improvements since last year, and the Ministry of Health and Welfare has been reviewing since April this year whether prices should be adjusted. However, supply concerns remain, with surgeries being delayed even for products for which no official supply-disruption report has been filed. 

◇Medical community blames low domestic prices, while government remains cautious about increases
Medical professionals and companies cite low treatment-material prices as a major cause of supply instability. According to data from the Korean Hydrocephalus Research Society, the upper limit for national health insurance reimbursement for domestic shunt kits was about 940,000 won as of November 2023. The figure was about 2.46 million won in Taiwan, about 2.02 million to 2.63 million won in Japan, and about 3.40 million to 4.03 million won in Australia. 

The medical community argues that low domestic prices may cause South Korea to fall behind in overseas manufacturers' supply priorities and delay the introduction of new products. B. Braun Korea also said that proGAV 2.0 was launched overseas in 2014 but domestic supply began in 2022, citing the low insurance reimbursement ceiling and other factors as reasons for the delay.

The Ministry of Health and Welfare, while acknowledging that domestic prices are lower than those overseas, said that after reviewing the import prices submitted by companies and other information, there is currently no clear basis for an increase.

Medical professionals are calling for a stable supply that allows shunts to be used for patients who need them at the time they need them. Jang Won-seok said, "We are asking that necessary treatment materials be available when they are needed," adding, "This is precisely the kind of issue that should be examined from the perspective of essential medical care."